by Mark Curtis | Jan 7, 2014
. Welcome to your Update from the Clinic for the month of December. Athersys and NeoStem both confirm completion of enrollment for phase 2 studies while bluebird bio announces the first patient transplanted in its phase 1/2 study of HGB-205 in patients with...
by Natasha Davie | Dec 10, 2013
. The UK has previously committed to incorporating some sort of value based pricing into its reimbursement scheme to improve patient access to innovative medicines. With recent backtracking on this decision, as the Jan 2014 deadline for this integration approaches, we...
by Lisa Willemse | Dec 6, 2013
> To be, or not to be, that is the question: Whether ’tis Nobler in the mind to suffer The Slings and Arrows of outrageous Fortune, Or to take Arms against a Sea of troubles, And by opposing end them We know this famous soliloquy from Shakespeare’s...
by Ben Paylor | Dec 5, 2013
> Just over two years ago I wrote about early reports from Dr. Roberto Bolli et al.’s SCIPIO trial running out of the University of Louisville in collaboration with the Harvard Medical School. Since this time, much has happened in the realm of cell therapy to treat...
by Nick Dragojlovic | Dec 2, 2013
> As the expiration of the California Institute for Regenerative Medicine’s (CIRM) funding approaches, the fate of CIRM after 2017 is top of mind for stem cell researchers in the state. While the agency’s leadership appears to be leaning towards some form of...
by Mark Curtis | Nov 19, 2013
. Welcome to October’s Update from the Clinic. Interesting developments this past month included the release of Phase 1/2a data from Living Cell Technologies that provides a first look at the safety and efficacy of its DIABECELL® product. We also saw an approval for...
Comments